Actor Rebel Wilson appeared in Sydney this September wearing a black pant co-ord that accentuated a figure approximately 80 pounds lighter than her 2020 baseline, Daily Express US reported.
The public appearance followed the April release of her memoir Rebel Rising, which became a New York Times bestseller, and her March 2024 disclosure that she used the GLP-1 receptor agonist semaglutide — marketed as Ozempic for type 2 diabetes — off-label to help maintain the weight loss she began during a self-declared “year of health” four years earlier.
Emotional eating identified as primary driver
Wilson has said that sustained weight management required addressing psychological patterns rather than caloric restriction alone. “There’s no magic fix. I’d been on diets [and] I’ve been really good [about] exercising pretty much my entire life,” she told Us Weekly three months after her book launch.
“For me, it was the emotional element that I’d never looked at. I’d kind of been, like, ‘Emotions… Ugh, I don’t want to talk about things.'”

The actor previously acknowledged relying on food to cope with stress and emotions, a behavior clinicians classify as emotional eating — a maladaptive coping mechanism distinct from homeostatic hunger. She also noted normal weight fluctuations tied to work stress, motherhood, and lifestyle changes.
In Plain English: The Clinical Takeaway
- GLP-1 medications like semaglutide regulate appetite by mimicking a gut hormone that signals satiety to the brain, but they do not resolve the psychological drivers of overeating.
- Sustained weight maintenance typically requires concurrent behavioral therapy to address emotional eating patterns.
- Off-label prescribing for obesity is common, but formal indications (such as Wegovy for chronic weight management) carry specific dosing protocols and monitoring requirements.
Pharmacology and regulatory context
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Its mechanism of action includes glucose-dependent insulin secretion, suppression of glucagon, slowed gastric emptying, and hypothalamic appetite regulation. The FDA approved Ozempic for type 2 diabetes in 2017; a higher-dose formulation (Wegovy) received approval for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity in 2021.
“GLP-1 receptor agonists are powerful tools, but they are not a substitute for comprehensive obesity care that includes behavioral support, nutritional counseling, and treatment of comorbid conditions.”
Clinical evidence and safety profile
| Parameter | Semaglutide 2.4 mg (STEP 1) | Placebo (STEP 1) |
|---|---|---|
| Discontinuation due to adverse events | Low percentage | Very low percentage |
| Serious adverse events | Low percentage | Low percentage |
Contraindications & When to Consult a Doctor
- Severe gastrointestinal disease (e.g., gastroparesis) may worsen with delayed gastric emptying.
- Pregnancy and breastfeeding: discontinue at least two months before planned pregnancy due to long half-life.
- Seek immediate care for persistent severe abdominal pain (possible pancreatitis), vision changes, or signs of allergic reaction.
From “Fat Amy” to health advocacy
Wilson rose to prominence as Brynn in Bridesmaids (2011) and as “Fat Amy” across the Pitch Perfect franchise (2012–2017), roles that centered her comedic persona on body size. Her 2020 “year of health” declaration marked a shift toward public discussion of metabolic health rather than aesthetics.
In October 2024, she attended the Pussycat Dolls reunion at London’s O2 Arena in leather trousers and a Burberry blouse, posting on Instagram: “Pussycat Dolls crushed O2 Arena last night! Massive props to my GURLFRIENDS @nicolescherzinger @iamashleyroberts for having us – their talents are literally through the roof!”
“The fact that it became a New York Times bestseller [and] the audiobook has been going insane — it’s done really, really well,” Wilson told Us Weekly of her memoir’s reception.
References
- Wilding JPH, et al.
- June 4, 2021.
- Davies MJ, et al.